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ficiency and in children with primary hyperoxaluria.
Background. Calcium-oxalate (CaOx) deposition and systemic
oxalosis are uncommon in children with chronic renal failure
(CRI), but frequent in children with primary hyperoxaluria type I
(PH-1). We hypothesized a difference in plasma CaOx saturation
(bCaOx) and its determining factors would explain this discrep-
ancy.
Methods. Therefore, in addition to common biochemical mea-
surements, plasma-oxalate (POx), citrate (PCit) and sulfate (PSulf)
(plasma anions) were measured and bCaOx was calculated in 17
PH-1 patients with normal renal function receiving pyridoxine and
citrate therapy, in 54 children with CRI (SCr 0.9 to 5.9 mg/dl), and
in 50 healthy children (NL). Plasma anions were analyzed by
ion-chromatography and bCaOx was calculated using a PC-based
program for solution equilibria.
Results. Compared to NL, all plasma anion levels and bCaOx
were higher in PH-1 and CRI; POx, PCit and bCaOx were higher in
PH-1 than in CRI (P , 0.05), but PSulf was higher in CRI (P ,
0.01). bCaOx and POx were correlated in all groups (r 5 0.63 to
0.95, P , 1024). POx and bCaOx were both inversely correlated to
a decrease in GFR in CRI patients. PCit and PSulf did not
influence bCaOx. Although supersaturation (bCaOx . 1) was found
in 7 CRI and in 4 PH-1 patients, eye examinations were suspicious
for CaOx depositions only in the PH-1 patients, while systemic
oxalosis was confirmed in one PH patient because of oxalate
osteopathy.
Conclusions. In PH-1, POx and bCaOx are elevated even with
normal renal function, which increases the likelihood of CaOx
crystal deposition. Therefore, more effective therapy to decrease
bCaOx is crucial to reduce the risk of systemic oxalosis. In children
with CRI unknown, but presumably protective substances, help
prevent the risk of systemic oxalosis, despite increased POx and
bCaOx levels, often to supersaturation levels.
Plasma oxalate (POx) elevation occurs either because of
endogenous oxalate overproduction, as in patients with
primary hyperoxaluria (PH-1 and -2), or because of a
reduction in urinary oxalate excretion, such as in patients
with chronic renal insufficiency (CRI) [1–6]. Calcium-
oxalate (CaOx) tissue deposition, however, is uncommon in
the latter group (CRI), but frequent in patients with PH,
especially when renal function deteriorates [4, 6, 7].
The relative level of plasma CaOx saturation (bCaOx) is
felt to be the most important factor for the development of
CaOx tissue deposition and systemic oxalosis [5, 7]). Previ-
ous studies have demonstrated an inverse relationship
between glomerular filtration rate (GFR) and bCaOx, but
with a substantial discrepancy between patients with pri-
mary hyperoxaluria or CRI. Thus, a decrease in glomerular
filtration rate (GFR) below 35 ml/1.73 m2/24 hr in patients
with PH-1, but only below 8 ml/1.73 m2/24 hr in non-PH-1
patients, was reported to be associated with a marked
increase in bCaOx (.1) [8, 9]. Further, CaOx supersatura-
tion and subsequent CaOx crystal deposition was observed
predominantly in PH-1 patients [4, 6, 7]. While CaOx
deposits have only been found to a minor degree in
non-PH-1 patients with end-stage renal failure, systemic
oxalosis does not develop [10, 11].
We hypothesized that there would be a difference in
bCaOx and its determining factors in children with PH-1 and
normal renal function and in those with mild to moderate
CRI unrelated to hyperoxaluria, which might explain this
noted discrepancy in the development of systemic oxalosis.
Therefore, in addition to common biochemical measure-
ments, we measured POx, as well as plasma citrate (PCit)
and sulfate (PSulf), two potential inhibitors of CaOx precip-
itation [12], and calculated bCaOx in these two groups of
children. The results were compared to values that we
obtained previously in healthy children [13].
METHODS
Blood was obtained in 17 patients with primary hyper-
oxaluria and normal renal function (12 girls, 5 boys, aged
2.5 to 16.4 years), and in 54 children with mild to moderate
renal insufficiency due to diverse diseases unrelated to
hyperoxaluria (18 girls, 36 boys, aged 0.8 to 18.8 years, SCr
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0.9 to 5.9 mg/dl; Table 1) after informed consent was
obtained at the participating children’s hospitals in Chi-
cago, Illinois, USA, and in Hamburg and Hannover, Ger-
many. Patients with PH-1 received pyridoxine (300 to 600
mg/m2/day) and oral citrate (0.5 mEq/kg/day). Dietary
intakes were not restricted for the purposes of this study.
The study was approved by the Institutional Review Board
of the Children’s Memorial Hospital in Chicago, Illinois,
USA.
Retinal examinations for potential CaOx depositions
were performed regularly in the patients. Retinal oxalosis
can be a sign of systemic oxalosis [14]. It is, however,
diagnosed more commonly in patients with a severe form of
PH-1 (infantile oxalosis) or in PH-1 patients with early
renal failure [14, 15]. X-ray films, available because of
clinical reasons in 13 of 17 PH-1 patients and in 45 of 54
CRI patients, were also screened for the typical signs of
oxalate osteopathy [16].
Plasma preservation and specimen shipping (all samples
were analyzed in Chicago) were performed as previously
described [13]. Plasma oxalate, citrate, sulfate and phos-
phate (PPhos) levels were determined by single sample,
sequential, ion-chromatography [13]. In addition to the
plasma anion concentrations, serum levels of total calcium
(SCa), magnesium, sodium, potassium, chloride, bicarbon-
ate and the free-flowing venous pH were measured in each
participant by a routine lab procedure [17]. Serum creati-
nine was determined using a modified Jaffe´ method and
glomerular filtration rate was calculated using the formula
of Schwartz et al [18].
bCaOx was calculated, entering the total concentration
(mmol/liter) of each of these parameters and a constant for
ammonium (NH4 5 0.01) into a PC-based program for
complex solution equilibria. For this purpose, an equilib-
rium program to calculate urine saturation (EQUIL) [12,
19, 20] was modified according to Marangella et al [7]. The
modified program uses a mass balance equation step to
estimate all main soluble complex formations possibly
formed by the input parameters. It expresses the state of
saturation as the factor of the calculated free calcium (Cca)
and oxalate (Cox) concentration, divided by the actual
solubility product (K9sp.CaOx) at the actual ionic strength of
the plasma sample [7, 21]:
bCaOx 5
CCa 3 COx
K9sp.CaOx
Plasma anion levels are expressed in mmol/liter (SE) and
bCaOx in relative units (SE). bCaOx above 1 is denoted as the
cut-off point above which supersaturation exists [7, 8]. The
values obtained were compared to normal values previously
determined by us in 50 healthy infants and children using
the same ion-chromatographic method [13]. bCaOx in those
healthy infants and children (NL, 23 girls, 27 boys, aged 0.2
to 17.0 years) was calculated for the current study by
entering the values from our previous study [13] and those
measured for the current study into the modified equilib-
rium program used herein [7].
The Mann-Whitney rank sum test and the Kruskall-
Wallis one way Analysis of Variance on ranks test were
used for analyses of the three groups (PH-1, CRI, NL).
Simple correlation analysis was performed by least squares
linear regression and confirmed by stepwise linear regres-
sion between all plasma anions and the bCaOx, and between
SCr or GFR, the plasma anions and bCaOx, respectively. All
statistical analyses were performed on a PC (SigmaStat;
SPSS Inc., Chicago, IL, USA). P values less than 0.05 were
considered to be significant.
RESULTS
When compared to healthy infants and children, all
plasma anion concentrations measured chromatographi-
cally were elevated in children with CRI, and, except for
phosphate, in children with PH-1 (Tables 2 and 3). The
mean bCaOx was elevated in the two patient groups, rising
threefold and twofold above normal in PH-1 and CRI,
respectively (Table 2). Pox was increased 18.1%, PCit was
increased 12.4% and bCaOx was increased 18.8% in PH-1
when compared to CRI (P , 0.05 for POx and PCit, P , 0.02
for bCaOx; Table 2). PSulf was higher in CRI than in PH-1
patients (P , 0.01; Table 2).
In CRI a rising POx was directly correlated to the
increase in SCr (r 5 0.60, P , 10
24) and to the decrease in
calculated GFR (r 5 0.55, P , 1024; Fig. 1). As expected,
a decline in GFR was correlated with an increase in both
PSulf (r 5 0.63; P , 10
24) and plasma phosphate (r 5 0.31;
P , 0.05). The rise in bCaOx was correlated directly to SCr
Table 1. Selected characteristics of study participants
N Age years
Serum creatinine
mg/dl
GFR ml/min/
1.73 m2
PH-1 17 8.4 (2.5–16.4) 0.68 (0.4–0.9) 105.6 (86.2–123.6)
CRI 54 10.9 (0.8–18.8) 2.08 (0.9–5.9) 45.4 (11.5–79.6)
NL [13] 50 9.2 (0.2–17) 0.6 (0.25–1.0) 112.3 (74.3–157.8)
Values reported are median (range). Glomerular filtration rate (GFR)
is calculated by the method of Schwartz et al [18]. Abbreviations are:
PH-1, primary hyperoxaluria type 1; CRI, chronic renal insufficiency; NL,
normal.
Table 2. Selected plasma anion levels and bCaOx in study participants
Oxalate Citrate Sulfate
bCaOx relative
unitsmmol/liter
PH-1 17.1 (1.6)a,c 127.7 (6.8)a,c 346.6 (38.1)b 0.64 (0.07)a,d
CRI 14.0 (1.21)a 111.9 (7.0)b 633.9 (65)a,e 0.52 (0.05)a
NL 6.43 (0.15) 79.3 (3.7) 235.0 (11.7) 0.23 (0.006)
POx, PCit, PSulf and bCaOx in healthy children (NL, [13])
a P , 1024 vs. NL; b P , 0.02 vs. NL; c P , 0.05 PH-1 vs. CRI, d P , 0.02
PH-1 vs. CRI, e P , 0.01 CRI vs. PH-1
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(r 5 0.58, P , 1024) and inversely correlated to calculated
GFR in children with CRI (r 5 0.55, P , 1024; Fig. 2).
bCaOx correlated significantly with POx in all groups
(PH-1, r 5 0.92; RI, r 5 0.95; NL, r 5 0.63, P , 1024 for
each; Fig. 3). It remained independent of SCa and PPhos,
however. Despite measured differences in PSulf and PCit,
neither contributed substantially to the measured bCaOx as
modeled in the equilibrium program.
Metabolic acidosis was observed in 14 children with CRI,
and was actively treated. Acidosis, however, did not influ-
ence either bCaOx or PCit, the latter expressed by a lack of
correlation between PCit and bicarbonate (r 5 0.20, NS) or
the free-flowing venous pH (r 5 0.08, NS).
The plasma was supersaturated (bCaOx . 1) in 4 children
with PH-1 (age 2.5 to 5.7 years) and in 7 children (age 5.5
to 15.4 years) with CRI (Fig. 2). In 4 of the PH-1 children
(one with bCaOx , 1) eye examinations were suspicious for
retinal calcium-oxalate deposits, and systemic oxalosis was
present in one patient because of oxalate osteopathy. None
of the children with CRI, however, showed signs of systemic
oxalosis.
As POx levels were significantly correlated with bCaOx,
plasma oxalate above 28 mmol/liter in both CRI and PH-1
patients were observed to be the cut-off point for the risk to
develop relative CaOx supersaturation (Fig. 3). A specific
prediction at which reduced level of kidney function bCaOx
would reach supersaturation was not possible, however, as
supersaturation in CRI was scattered over a wide range of
GFR (Fig. 2).
Table 3. Plasma concentrations of relevant parameters entered in the PC-based program for complex solution equilibria to calculate bCaOx
Ca Mg Na K Cl PO4 CO2
pHmmol/liter
PH-1 2.48 (0.03) 0.80 (0.01) 140.4 (0.51) 4.18 (0.15) 104.5 (0.90) 1.34 (0.09) 23.6 (0.45) 7.37 (0.010)
CRI 2.46 (0.02) 0.83 (0.02) 140.0 (0.48) 4.49 (0.07) 107.8 (0.61) 1.53 (0.06)a 23.8 (0.54) 7.35 (0.006)
NL 2.48 (0.03) 0.80 (0.02) 139.9 (0.42) 4.30 (0.08) 105.0 (0.58) 1.06 (0.03) 24.4 (0.49) 7.36 (0.004)
a P , 0.05 CRI vs. NL
Fig. 1. Relationship between GFR and POx in children with CRI (N 5 54,
r 5 0.55, P < 1024). The solid line is the regression obtained by the
least-squares method.
Fig. 2. Relationship between GFR and bCaOx in children with CRI (N 5
54, r 5 0.55, P < 1024). The solid line is the regression obtained by the
least-squares method.
Fig. 3. Relationship between POx and bCaOx in children (N 5 17) with
primary hyperoxaluria (F, ——, r 5 0.92, P < 1024) and in children (N 5
54) with CRI (E, – z z –, r 5 0.95, P < 1024). The slopes of the two lines
do not differ (P 5 NS).
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DISCUSSION
In patients with primary hyperoxaluria, POx and bCaOx
were elevated, even with preserved renal function. Al-
though PCit increased with oral citrate therapy in these
children, it did not lower bCaOx significantly in patients with
PH-1. CaOx supersaturation was found in four patients
with PH-1 while eye examinations were suspicious for
CaOx deposition in four children (one without supersatu-
ration) and systemic oxalosis was diagnosed in one patient
with x-rays typical for oxalate osteopathy. In CRI unknown,
but presumably protective substances help prevent the risk
of systemic oxalosis, despite increased POx levels and CaOx
supersaturation. We conclude that a difference in bCaOx
does not explain the entire discrepancy of CaOx crystal
deposition in these two groups of patients.
Our finding that plasma oxalate levels are already ele-
vated in PH-1 patients with preserved renal function is
known, but not well addressed, in prior studies. We dem-
onstrated that such an elevation of POx, even in children
with preserved renal function, led to an elevated bCaOx,
which increases the risk of possible CaOx depositions.
Therefore, early diagnosis and effective therapeutic options
beyond oral citrate therapy are quite important to prevent
systemic oxalosis in these patients.
We observed an elevated bCaOx and occasional CaOx
supersaturation in children with CRI. The latter finding is
in contrast to previous observations in adults with similarly
diminished renal function, but without PH-1 [5, 7, 8].
Marangella et al calculated slightly supersaturated bCaOx
levels in adults at ESRD [22], and supersaturation was said
to only occur with a GFR below 8 ml/min/1.73 m2 [8].
Worcester et al demonstrated supersaturated bCaOx levels
in adults only with SCr levels above 9 mg/dl [5]. POx levels
above 40 to 50 mmol/liter have been correlated with the risk
of CaOx supersaturation in adults [5, 8]. We observed
bCaOx supersaturation to be present in children with only
moderate reductions in renal function (Fig. 2) and with POx
levels as low as 28 mmol/liter. Interestingly, none of our
children with CRI had signs of CaOx accumulation and
deposition, which is comparable to experiences in adult
patients [4, 5, 8]. Tomson et al, for example, reported POx
levels ranging from 6 to 116 mmol/L in CRI patients, but
could not find CaOx deposits [4]. CaOx deposition has been
reported in adults at ESRD and with tissue damage [23]
and due perhaps to local oxalate production by such organs
themselves [24]. Therefore, other parameters than bCaOx
and POx may be of importance in selected circumstances in
CRI.
CaOx crystal deposition can start early in PH-1 patients.
Therefore, it is important to know when the risk of CaOx
deposition increases. In this respect, the level of CaOx
supersaturation is felt to be the major determining factor of
such deposition [5, 7]. An exceeding of the CaOx solubility
product (bCaOx . 1) represents an absolute risk for CaOx
crystal deposition in body tissue [5]. Therefore, our dem-
onstration that supersaturation occurs quite early in the
course of PH-1 is important clinically. This was further
substantiated, as we found CaOx supersaturation in four of
our PH-1 patients and with tissue deposition present
already.
We had speculated that citrate and sulfate, which are
known to be potent inhibitors of urinary CaOx precipita-
tion, would help to either decrease bCaOx or to protect
against CaOx deposition [12]. In fact, that is one rationale
for oral citrate therapy in such patients. Although both
parameters are elevated in CRI and in PH-1, with the
highest level of citrate in PH-1 patients using citrate
therapy, bCaOx was not adequately lowered in either group.
Urine has a higher potential than plasma to inhibit a
nucleation process, as citrate concentration for example, is
ten times higher in urine than in plasma [12]. Therefore,
the degree of CaOx supersaturation necessary to initiate
crystal deposition may be lower in plasma than in urine.
Alternatively, PCit would have to be raised to . 1 mM to
reduce bCaOx. This is unlikely to be achievable with oral
citrate therapy alone.
In conclusion, elevated POx and bCaOx levels in PH-1
patients with normal renal function increase the risk of
early CaOx accumulation and crystal deposition. POx itself
is the most important parameter that influences the rise in
bCaOx. Therefore, more effective therapy to decrease bCaOx
is crucial to reduce the risk of systemic oxalosis in PH-1. In
CRI unknown, but presumably protective substances may
help prevent the risk of CaOx deposition in children,
despite increased POx and bCaOx levels sometimes above
supersaturation. Further studies are clearly needed to
evaluate the role of other possible factors in the risk of
CaOx deposition in PH-1 compared to CRI, including time
of such exposure to CaOx supersaturation.
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